The extended approvals in the EU and the effects of good marketing in the USA , and tonight in Paris, together with penetration in Asia and MENA will certainly accelerate the number of centres using and re-ordering the product.
South America, China and particularly India, Japan and Korea will be next.
Whether its 135, 150 or 500+ centres is something I will wait for in confidence.
Then extrapolate the numbers from what is mainly CHD usage and centre numbers now into wider vascular, valve, CABG, stem cell delivery , dura mata and other applications.
Such a great future unfolding for ADAPT technology.
Fox
Err! Sounds lime pumping...but honestly heartfelt comments.
Centres by end of year?, page-5
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$11.33 |
Change
-0.100(0.87%) |
Mkt cap ! $239.5M | |||
| Open | High | Low | Value | Volume |
| $11.45 | $11.50 | $11.33 | $11.79K | 1.031K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 154 | $11.33 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $11.49 | 639 | 1 |
View Market Depth
| Last trade - 10.18am 15/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |